StockData
BlossomHill Therapeutics, Inc. logo

BlossomHill Therapeutics, Inc. (BLSM) stock

BLSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$14.59−0.54 (-3.57%)

Close on Nov 18, 2026Market cap $37.18MP/E –Yield –

BlossomHill Therapeutics net income

Net income is the profit left for shareholders after every expense, interest and tax.

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$23.76M–
Q2 FY2025Jun 30, 2025-$13.24M–

More BlossomHill Therapeutics figures

See a number that looks wrong?